Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Ocala, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Port Charlotte, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Tampa, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Chicago, IL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Hoffman Estates, IL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Lexington, KY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Baltimore, MD
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Columbia, MD
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Columbia, MD
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Boston, MA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Golden Valley, MN
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Omaha, NE
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Albany, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
New York, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Syracuse, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Toledo, OH
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Allentown, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Upland, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Upland, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Dallas, TX
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Margolin Brain Institute
mi
from
Fresno, CA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Margolin Brain Institute
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
The Parkinson's Institute in Sunnyvale
mi
from
Sunnyvale, CA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
The Parkinson's Institute in Sunnyvale
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Charlotte Neurological Services
mi
from
Port Charlotte, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Charlotte Neurological Services
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
University Health Systems
mi
from
Las Vegas, NV
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
University Health Systems
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Parkinson's Disease and Movement Disorders Center of Long Island
mi
from
Commack, NY
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Parkinson's Disease and Movement Disorders Center of Long Island
mi
from
Commack, NY
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Kingston Neurological Associates
mi
from
Kingston, NY
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Kingston Neurological Associates
mi
from
Kingston, NY
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
University Neurology, Inc
mi
from
Cincinnati, OH
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
University Neurology, Inc
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Sentara Neurological Associates
mi
from
Virginia Beach, VA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Sentara Neurological Associates
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
UM Movement Disorders Center
mi
from
Miami, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
UM Movement Disorders Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
USF Parkinson's & Movement Disorders Center
mi
from
Tampa, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
USF Parkinson's & Movement Disorders Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
QUEST Research Institute
mi
from
Bingham Farms, MI
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
QUEST Research Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Hôpital Gabriel Montpied-Service de Neurologie A-
mi
from
Clermont-Ferrand Cedex 1,
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Hôpital Gabriel Montpied-Service de Neurologie A-
mi
from
Clermont-Ferrand Cedex 1,
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Colorado Denver
mi
from
Aurora, CO
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated:  9/12/2017
Xenoscience Inc.
mi
from
Phoenix, AZ
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated: 9/12/2017
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated:  9/12/2017
Compass Research LLC
mi
from
Orlando, FL
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated: 9/12/2017
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD
Status: Enrolling
Updated:  9/27/2017
Universtiy of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory
mi
from
Ann Arbor, MI
Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD
Status: Enrolling
Updated: 9/27/2017
Universtiy of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Effects of Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Status: Enrolling
Updated:  9/28/2017
NYIT
mi
from
Old Westbury, NY
Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Effects of Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Status: Enrolling
Updated: 9/28/2017
NYIT
mi
from
Old Westbury, NY
Click here to add this to my saved trials
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease
Status: Enrolling
Updated:  10/2/2017
Cleveland Clinic
mi
from
Cleveland, OH
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease
Status: Enrolling
Updated: 10/2/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment of Executive Dysfunction in Parkinson's Disease
Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study
Status: Enrolling
Updated:  10/2/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Treatment of Executive Dysfunction in Parkinson's Disease
Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study
Status: Enrolling
Updated: 10/2/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
COPE-Co-morbidities, Parkinson's Disease and Exercise
COPE-Co-morbidities, Parkinson's Disease and Exercise
Status: Enrolling
Updated:  10/6/2017
OHSU
mi
from
Portland, OR
COPE-Co-morbidities, Parkinson's Disease and Exercise
COPE-Co-morbidities, Parkinson's Disease and Exercise
Status: Enrolling
Updated: 10/6/2017
OHSU
mi
from
Portland, OR
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Birmingham, AL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Sun City, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Sun City, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials